🔴 Absci is trading 5.18% down today after Q2 revenue missed and losses exceeded forecasts

Absci is trading 5.18% down now at $8.97 as investors continue digesting the August 11 earnings report and its disappointment.

• Q2 revenue was $0.3 million versus approximately $1.01 million expected; the $0.21 per-share loss exceeded the $0.19 forecast.
• The report initially triggered a 17.43% after-hours decline, despite positive ABS-201 data, Eli Lilly’s $40 million investment, and cash runway extending into late 2028.
• The broader market is modestly weaker, but the earnings disappointment is the clearest catalyst.